Zevalin ibritumomab tiuxetan cancer data

Data from a trial in 8 evaluable patients with low-grade

Read the full 103 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE